Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio. Headquartered in Switzerland, Windward Bio is a ...
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Hosted on MSN19h
AerWave Medical concludes study of ultrasound therapy for COPDThe study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
23h
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback